Free Trial

RxSight (NASDAQ:RXST) Rating Lowered to "Market Perform" at Oppenheimer

RxSight logo with Medical background

Oppenheimer lowered shares of RxSight (NASDAQ:RXST - Free Report) from an outperform rating to a market perform rating in a report published on Wednesday, MarketBeat.com reports.

Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. reissued an "underweight" rating and issued a $17.00 price objective (down previously from $40.00) on shares of RxSight in a research note on Friday, April 4th. Bank of America reissued an "underperform" rating and issued a $22.00 price objective (down previously from $36.00) on shares of RxSight in a research note on Thursday, April 3rd. UBS Group downgraded shares of RxSight from a "buy" rating to a "neutral" rating and decreased their price target for the company from $45.00 to $16.00 in a research note on Wednesday, April 9th. Stifel Nicolaus cut their price objective on shares of RxSight from $33.00 to $28.00 and set a "hold" rating on the stock in a report on Wednesday, March 19th. Finally, Wells Fargo & Company lowered shares of RxSight from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $25.00 to $9.00 in a report on Wednesday. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, RxSight presently has a consensus rating of "Hold" and a consensus price target of $23.90.

Check Out Our Latest Report on RxSight

RxSight Trading Up 5.0%

Shares of NASDAQ:RXST traded up $0.40 during trading on Wednesday, reaching $8.35. The company's stock had a trading volume of 2,646,091 shares, compared to its average volume of 978,627. RxSight has a 12 month low of $6.32 and a 12 month high of $58.23. The firm's 50 day simple moving average is $14.26 and its two-hundred day simple moving average is $22.38. The stock has a market capitalization of $339.34 million, a PE ratio of -12.46 and a beta of 1.21.

RxSight (NASDAQ:RXST - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.03) EPS for the quarter, meeting analysts' consensus estimates of ($0.03). RxSight had a negative net margin of 17.90% and a negative return on equity of 9.54%. The firm had revenue of $37.90 million during the quarter, compared to the consensus estimate of $38.74 million. During the same quarter last year, the firm earned ($0.25) EPS. The firm's revenue for the quarter was up 28.5% compared to the same quarter last year. Research analysts anticipate that RxSight will post -0.7 EPS for the current fiscal year.

Institutional Investors Weigh In On RxSight

Large investors have recently made changes to their positions in the stock. GAMMA Investing LLC grew its holdings in shares of RxSight by 12,990.8% during the first quarter. GAMMA Investing LLC now owns 8,509 shares of the company's stock valued at $215,000 after buying an additional 8,444 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of RxSight during the first quarter valued at $916,000. Vanguard Group Inc. grew its holdings in shares of RxSight by 4.2% during the fourth quarter. Vanguard Group Inc. now owns 2,383,548 shares of the company's stock valued at $81,946,000 after buying an additional 96,464 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of RxSight by 10.0% during the fourth quarter. Bank of New York Mellon Corp now owns 102,882 shares of the company's stock valued at $3,537,000 after buying an additional 9,385 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of RxSight by 23.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 84,958 shares of the company's stock valued at $2,921,000 after buying an additional 16,140 shares during the last quarter. 78.78% of the stock is owned by hedge funds and other institutional investors.

RxSight Company Profile

(Get Free Report)

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

Read More

Analyst Recommendations for RxSight (NASDAQ:RXST)

Should You Invest $1,000 in RxSight Right Now?

Before you consider RxSight, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list.

While RxSight currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines